Skip to main content
Live
Markets 392694
Platforms 2
Active Arbs 85
Volume $10.0B

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2027?

kalshi other Ends Jul 1, 2027 (7mo left) Vol: $75 • LIVE · Nov 17, 2026 03:54 UTC
Yes price
10¢
No price
90¢
Bid 10¢ Ask 18¢ Mid 14¢ OI $42
Trade on kalshi Run arbitrage calculator → See all live arbs →

About this market: Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jul 1, 2027? is currently priced at 10¢ for Yes and 90¢ for No on kalshi, in the other category. It resolves on Jul 1, 2027 (7mo from now). Daily volume is around $75. No matched market was found on the other platform yet.

Cross-Platform Prices

More other markets

All other markets →